Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 623.50
Change Today -53.50 / -7.90%
Volume 437.2K
RDHL On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Tel Aviv
As of 10:24 AM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Open
$648.00
Previous Close
$677.00
Day High
$654.00
Day Low
$619.90
52 Week High
06/15/15 - $910.10
52 Week Low
11/18/14 - $295.00
Market Cap
774.5M
Average Volume 10 Days
502.8K
EPS TTM
$-0.21
Shares Outstanding
124.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company’s pipeline of therapeutic candidates include RHB-105, which is in Phase III clinical trial, intended for the eradication of Helicobacter pylori infection; and RHB-104 that is in Phase III clinical trial for the treatment of Crohn's disease, in Phase IIa proof of concept clinical trial for the treatment of multiple sclerosis, and under pre-clinical studies for the treatment of rheumatoid arthritis. Its pipeline of therapeutic candidates also comprise BEKINDA, which is under review with FDA, for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and in Phase III clinical trial for the treatment of gastroenteritis and gastritis; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. In addition, the company’s pipeline of therapeutic candidates consist of MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers, which has completed various Phase I clinical trials and two Phase II proof of concept clinical trials; RP101, a heat shock protein 27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers, which has completed various Phase I and Phase II clinical trials; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. Further, its pipeline of proprietary products comprises ABC294640, a Phase II-stage orally-administered sphingosine kinase-2 inhibitor targeting various inflammatory, gastrointestinal, and oncology indications. The company was founded in 2009 and is based in Tel Aviv, Israel.

10 Employees
Last Reported Date: 02/26/15
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $280.2K
Deputy Chief Executive Officer of Finance & O...
Total Annual Compensation: $237.6K
Senior Vice President of Research & Developme...
Total Annual Compensation: $233.2K
Senior Vice President of Corporate & Product ...
Total Annual Compensation: $216.0K
Chief Business Officer
Total Annual Compensation: $199.3K
Compensation as of Fiscal Year 2014.

redhill biopharma ltd (RDHL) Key Developments

RedHill Biopharma Mulls Acquisitions

RedHill Biopharma Ltd. (TASE:RDHL) is seeking acquisitions. RedHill Biopharma Ltd. has filed a follow-on equity offering. Gross proceeds from the sale of the ADSs by RedHill before underwriting discounts and commissions and other offering expenses are expected to be approximately $40 million. The Company intends to use the proceeds from the offering for research and development related purposes in connection with RedHill's therapeutic candidates, for potential acquisitions and general corporate purposes.

RedHill Biopharma Eyes Acquisitions

RedHill Biopharma Ltd. (TASE:RDHL) is looking for acquisitions. The company has filed a Follow-on Equity Offering and intends to use the proceeds from the offering for research and development related purposes in connection with RedHill's therapeutic candidates, for potential acquisitions and general corporate purposes.

RedHill Biopharma Receives Authorization in Australia and New Zealand for Ongoing Phase III Crohn's Disease Study With RHB-104

RedHill Biopharma Ltd. announced that it has received regulatory authorization to commence patient enrollment in Australia and New Zealand for its ongoing Phase III study with RHB-104 for Crohn's disease (the MAP US study), and has commenced patient screening in New Zealand. RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The MAP US study is the first Phase III study with RHB-104 for the treatment of Crohn's disease, currently ongoing in the U.S. and additional countries. With over 80 of the 120 planned clinical sites already active worldwide, the ongoing randomized, double-blind, placebo-controlled MAP US study is expected to enroll 270 patients with moderately to severely active Crohn's disease. Patients are randomized 1:1 to receive either RHB-104 or a placebo for 52 weeks and evaluated for the primary endpoint of remission at week 26 of treatment. Interim analysis of the MAP US study is expected in the second half of 2016 after half of the patients expected to be enrolled in the study will have completed 26 weeks of treatment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 623.50 -53.50

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies
 

Industry Analysis

RDHL

Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit www.redhillbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.